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BACKGROUND
The newborn screening (NBS) programme is a 
complex and organised system consisting of family 
and personal education, biochemical tests, confi rma-
tory biochemical and genetic tests, diagnosis, therapy, 
and patient follow-up. The programme identifi es 
treatable metabolic disorders, possibly when still as-
ymptomatic, by using dried blood spot (DBS). Over 
the last 20 years, tandem mass spectrometry (TMS) 
has become the leading technology in NBS pro-
grammes and has been shown to be versatile, sensitive 
and specifi c. There is consistent evidence of benefi ts 
from NBS for many disorders detected by TMS as 
well as for congenital hypothyroidism, cystic fi brosis 
and congenital adrenal hyperplasia by immune-enzy-
matic methods. Some methods were developed for the 
detection of lysosomal storage disorders (LSDs), and 
even if for some of them there is a reliable and rela-
tively simple test, a reasonable associated therapy 
may still not be available. Therefore the inclusion of 
LSDs in NBS is still under debate.
MATERIALS AND METHODS
At the beginning of the 2000’s, fl uorometric meth-
ods were developed for many LSDs such as Pompe 
disease, Gaucher disease, Fabry disease, mucopoly-
saccharidosis (MPS), Hurler-like LSDs, Niemann-
Pick A/B disease, Tay-Sachs disease and Sandhoff 
disease. However, the incorporation of a chromophore 
or fl uorophore into the substrate caused false-negative 
results and had the limitations of specifi city and lim-
ited capacity for multiplexing. In recent years new 
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MS-based technology for simultaneous screening of 
several enzyme activities related to lysosomal storage 
disorders from DBS was developed, replacing the old 
methods and enabling the assay of single enzyme ac-
tivity. Li et al (1) fi rst developed a direct multiplex 
assay of lysosomal enzymes for Gaucher, Pompe, 
Krabbe, Fabry and Niemann-Pick A/B diseases in 
DBS by fl ow injection analysis (FIA) tandem mass 
spectrometry. Since then, an expansion of simultane-
ously diagnosable disorders by MS has been reported. 
Some countries already include some LSDs in their 
newborn screening panels, and local or pilot pro-
grammes have been launched in others. (2-6). 
CONCLUSIONS
It is currently debated whether or not LSD diseases 
should be included in a general NBS worldwide pro-
gramme. In 2014, most LDS pilot projects include 
Pompe disease. In general, NBS for LSD could iden-
tify asymptomatic forms; it is not able to discriminate 
between treatable and untreatable forms, surely it can-
not suggest if and when to start therapy. However, 
even if long-term clinical studies are not available, it 
seems that Pompe disease meets the criteria for inclu-
sion in NBS, including basal availability of a simple 
test, a combination therapy that modifi es the natural 
course of the disease, and early diagnosis that allows 
for genetic counsel ling and prenatal diagnosis in fam-
ilies with an affected baby.
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